Innovation Pharmaceuticals Inc.
company.status.inactiveCIK 1355250fmd_1EXRT9YYJH42R3NXARQN7VFQ82Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2007 to Sep 30, 2023, 56 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Operating income
- (3)
- Net income
- (3)
Latest quarter · Q1 FY2024
Millions- Total revenues
- 0
- Operating income
- (1)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- n/m
- Revenue, 5 yearsFY2018 to FY2023
- n/m
- Net income, 5 yearsFY2018 to FY2023
- n/m
Innovation Pharmaceuticals Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $18,000 | -100% | 10-K 2023-09-28 · proof |
| Operating income | -$3.1 million | -$6.9 million | 10-K 2023-09-28 · proof | |
| Net income | -$3.2 million | -$7 million | 10-K 2023-09-28 · proof | |
| Cash from operating activities | -$2.1 million | -$6.3 million | 10-K 2023-09-28 · proof | |
| Total assets | $7.5 million | $10.4 million | -27.6% | 10-K 2023-09-28 · proof |
| Total liabilities | $5.5 million | $5.6 million | -3% | 10-K 2023-09-28 · proof |
| Cash and cash equivalents | $1.5 million | $3.8 million | -60.1% | 10-K 2023-09-28 · proof |
- What was Innovation Pharmaceuticals Inc.'s revenue in fiscal 2023?
- Innovation Pharmaceuticals Inc. reported revenue of $0 for fiscal 2023 (the year ended Jun 30, 2023), against $18,000 the year before (-100%). Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What was Innovation Pharmaceuticals Inc.'s operating income in fiscal 2023?
- Innovation Pharmaceuticals Inc. reported operating income of -$3.1 million for fiscal 2023 (the year ended Jun 30, 2023), against -$6.9 million the year before. Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What was Innovation Pharmaceuticals Inc.'s net income in fiscal 2023?
- Innovation Pharmaceuticals Inc. reported net income of -$3.2 million for fiscal 2023 (the year ended Jun 30, 2023), against -$7 million the year before. Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What was Innovation Pharmaceuticals Inc.'s cash from operating activities in fiscal 2023?
- Innovation Pharmaceuticals Inc. reported cash from operating activities of -$2.1 million for fiscal 2023 (the year ended Jun 30, 2023), against -$6.3 million the year before. Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What are Innovation Pharmaceuticals Inc.'s total assets?
- As of Jun 30, 2023, Innovation Pharmaceuticals Inc. reported total assets of $7.5 million, against $10.4 million a year earlier (-27.6%). Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What are Innovation Pharmaceuticals Inc.'s total liabilities?
- As of Jun 30, 2023, Innovation Pharmaceuticals Inc. reported total liabilities of $5.5 million, against $5.6 million a year earlier (-3%). Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
- What are Innovation Pharmaceuticals Inc.'s cash and cash equivalents?
- As of Jun 30, 2023, Innovation Pharmaceuticals Inc. reported cash and cash equivalents of $1.5 million, against $3.8 million a year earlier (-60.1%). Source: the 10-K filed with the SEC on Sep 28, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1355250&period_type=annual&limit=5"Information only, not investment advice.